How should immunotherapy be incorporated into the treatment strategy for patients with resectable stage III microsatellite instability–high (MSI-H) or mismatch-repair-deficient (dMMR) extrahepatic cholangiocarcinoma?  

Great question and one that we do not have clear data to support but could certainly extrapolate. KEYNOTE 158 trial included 22 patients with advanced cholangiocarcinoma and response was 40.9% with median duration of response not reached (mOS 24.3months (6.5-NR)) (https://doi.org/10.1200/JCO.19.0210...